By: Dr. Anish ShahBronx-Lebanon Hospital; Bronx, NY On February 15, 2024, the U.S. Food and Drug Administration granted regular approval to tepotinib (Tepmetko)…
By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On February 13, 2024, the U.S. Food and Drug Administration granted approval for the…
By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On December 13, 2023, the U.S. Food and Drug Administration granted approval to eflornithine…
By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY The U.S. Food and Drug Administration gave its approval for the use of enfortumab…
By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On December 14, 2023, the U.S. Food and Drug Administration granted approval to belzutifan…
By Dr. Arya Mariam Roy of Roswell Park Comprehensive Cancer Center Tucatinib, a HER2-directed tyrosine kinase inhibitor (TKI), has been…
By Dr. Arya Mariam Roy of Roswell Park Comprehensive Cancer Center Development of endocrine resistance remains a challenge in the…
By Dr. Shipra Gandhi of Roswell Park Comprehensive Cancer Center Data from two phase III trials showed that adding immune…
December 6th 2023 / 12:15 PM PST By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On November 15, 2023, the U.S. Food…
The Binaytara Foundation has proudly announced the 2023 Binaytara Career Advancement Awards recipients. The recipients of the 2023 awards attended…